Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.49 |
| ▸ | REN | P00797 | 3/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CPA2 | P48052 | 1/20 | 0.46 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31119957 | 1.00 | BACE1 (0.49) | BACE1BACE2RENKEAP1OPRM1 | |
| SCHEMBL29991514 | 0.90 | BACE1 (0.53) | BACE1BACE2RENKEAP1OPRM1 | |
| SCHEMBL31609331 | 0.85 | MME (0.56) | RENOPRM1OPRD1CPA1CPB1 | |
| SCHEMBL29886195 | 0.81 | BACE1 (0.55) | BACE1BACE2RENOPRM1OPRD1 | |
| SCHEMBL30190513 | 0.78 | KEAP1 (0.67) | BACE1BACE2KEAP1OPRM1OPRD1 | |
| SCHEMBL30799592 | 0.77 | OPRM1 (0.60) | BACE1BACE2OPRM1OPRD1 | |
| SCHEMBL7421185 | 0.77 | CPA1 (0.59) | BACE1BACE2CPA1CPB1CPA2 | |
| SCHEMBL18087495 | 0.77 | CASP1 (0.63) | BACE1BACE2RENOPRD1 | |
| SCHEMBL24310825 | 0.77 | CASP1 (0.63) | BACE1BACE2RENOPRD1 | |
| SCHEMBL19970821 | 0.77 | CASP1 (0.63) | BACE1BACE2RENOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752196-B2 | Treatment of pyroptosis | JALAN RAJIV (GB) | 2023-09-12 | — | — | US | disclosed |
| US-20210069296-A1 | TREATMENT OF PYROPTOSIS | JALAN RAJIV (GB) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11752196-B2 | Treatment of pyroptosis | GSDMD, CASP1, CASP5 | BACE1 345/4885BACE2 1553/4885REN 2008/4885 |
| US-20210069296-A1 | TREATMENT OF PYROPTOSIS | GSDMD, CASP1, CASP5 | BACE1 345/4885BACE2 1553/4885REN 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.